DDInter1083 DDInter927
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lofexidine {u} (Compound) resembles {v} (Compound) Apraclonidine
Lofexidine {u} (Compound) binds {v} (Gene) ADRA2A
Lofexidine {u} (Compound) upregulates {v} (Gene) HMGA2
Lofexidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Lofexidine (Compound) resembles Apraclonidine (Compound)
Lofexidine (Compound) binds ADRA2A (Gene)
Lofexidine (Compound) upregulates HMGA2 (Gene)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Lofexidine may lead to a major life threatening interaction when taken with Ribociclib
Lofexidine may lead to a major life threatening interaction when taken with Toremifene